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1. Introduction 
Peptides influence numerous biological processes (acting as 
hormones, enzyme inhibitors, neurotransmitters, antibiotics…) that 
affect vital physiological functions and, therefore, constitute very 
valuable leads for drug design.[1] Moreover, the discovery of novel 
peptides, other than naturally occurring ones, is increasing because 
it is being simplified through the use of recombinant display 
technologies (phage, DNA/RNA...).[2] One reason for this 
expansion is that peptide-based drugs have the key advantage of 
diminishing problems related with toxicology and safety, which are 
two of the main causes of failure when developing drugs of non-
peptidic nature. However, the therapeutic application of bioactive 
peptides is often limited by their low oral bioavailability and poor 
distribution as well as by the lack of specificity for a particular 
receptor.[1,3] 
In order to overcome such limitations, the pharmacokinetic 
profiles of peptides have been modified mostly through chemical 
optimization strategies along with new routes of administration. In 
fact, the intense investigation made in both fields has led to more 
than sixty synthetic peptides currently available as drugs on several 
areas of the pharmaceutical market.[3a] 
In this context, the rational modification of the intrinsic 
physicochemical properties of peptides through the incorporation 
of non-coded amino acids is one of the chemical strategies of 
active investigation. This is due to the versatility of unnatural 
amino acid residues, which can be purposely conceived to improve 
peptide stability towards proteases, to enhance the ability to cross 
physiological membranes or to reduce conformational flexibility, 
and these changes often result in enhanced potency and specificity. 
Furthermore, the incorporation of non-proteinogenic residues into 
peptides assures chemical diversity, which is a key issue for 
generating patentable drugs. 
Among non-coded amino acids, proline analogues are of 
particular interest given the key role of proline in nucleating the 
secondary structure, and hence the function, of peptides.[4] In 
particular, octahydroindole-2-carboxylic acid (Oic) and its -
methylated counterpart [( Me)Oic] hold considerable interest due 
to their well-suited structural features (Figure 1). Their bicyclic 
structure introduces certain backbone rigidity when incorporated 
into peptides, similar to that induced by proline. This structural 
restriction may contribute not only to improve the resistance to 
degrading enzymes but also to enhance target binding and 
selectivity properties through the stabilization of specific secondary 
structural motifs. These properties may be particularly enhanced in 
the case of the -methylated derivative due to the tetrasubstituted 
character of the  carbon.[5] At the same time, both Oic and 
( Me)Oic are proline analogues endowed with greater lipophilicity 
and hydrophobic size, which may generate peptides exhibiting 
increased bioavailability or providing improved binding 
interactions at the receptor active site. 
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Figure 1. General structure of octahydroindole-2-carboxylic acid (Oic) and 
its -methyl derivative [( Me)Oic]. The position of the chiral carbons is 
indicated. 
In particular, Oic has already contributed to improve the 
enzymatic stability and potency of several Bradykinin B2 
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antagonists such as Icatibant (Figure 2), which has recently 
received European approval for the treatment of hereditary 
angioedema.[6] Moreover, Oic is a part of the suberimidyl dimer 
CU-201 (Figure 2), currently under development as a possible drug 
for lung cancer.[7] Oic is also present in the pentapeptide FM19 
(Figure 2), which is an orally active investigational drug able to 
inhibit platelet aggregation and is therefore of use in the 
management of acute coronary syndrome.[8] The ability of Oic to 
induce -turn motifs, which is operational in Icatibant,[6d] has also 
been used for the de novo design of selective antibiotic peptides.[9] 
Besides, the sterically constrained structure of this bicyclic proline 
analogue has proven useful to determine the physiological role of 
certain melanocortin receptors (hMCR) through the design of 
potent and selective agonists towards the receptor subtype 5 as, for 
example, compound OBP-MTII (Figure 2).[10]
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Figure 2. Examples of modified peptides containing Oic that exhibit pharmacologically relevant properties.
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In the field of peptidomimetic design, Oic has found application in 
the elaboration of medicinally relevant compounds such as 
perindopril[11] (Figure 3), an angiotensin-converting enzyme (ACE) 
inhibitor which is one of the top antihypertensive drugs on the 
market. Oic is also a part of a series of potent prolyl oligopeptidase 
(POP) inhibitors. Among them, S17092[12] (Figure 3) is under 
investigation for the treatment of neurodegenerative diseases like 
Alzheimer's and Parkinson's. Moreover, Oic is present in several 
potent and selective human leukocyte elastase (HLE) inhibitors 
that may provide a powerful in vivo protection against pulmonary 
tissue destruction.[13] 
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Figure 3. Some Oic-containing peptidomimetics with pharmacologically 
relevant properties. 
Besides, the octahydroindole-2-carboxylic acid scaffold 
containing additional functionalities is found in the structure of 
aeruginosins (Figure 4), a family of bioactive naturally-occurring 
alkaloids that act as thrombin, trypsin, and factor VIIa 
inhibitors.[14] Even if most of the aeruginosins discovered contain 
hydroxy groups at the azabicyclic unit, some unnatural surrogates 
incorporating unsubstituted Oic have been synthesized and found 
to exhibit increased activity against thrombin (Figure 4).[14c] 
N
H
H
aeruginosin 298-A
HO
HN
O
OH
HN
O
HO
O
iBu
N
H
H
unnatural aeruginosin
HN
O
HN
O
HO
O
Me
Me
H2N
NH
NH
HN
H2N
OH
 
Figure 4. Example of a naturally-occurring aeruginosin and a synthetic 
surrogate containing unsubstituted Oic. 
Additionally, compounds including an -methyl group anchored 
at the  carbon of the perhydroindole-2-carboxylic acid core 
(Figure 5) have been reported to exhibit potential applications for 
treating osteoarthritis.[15] 
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Figure 5. Example of a pharmacologically active ( Me)Oic derivative. 
Besides the attractiveness of Oic derivatives for drug generation 
outlined before, additional interest on these compounds stems from 
their potential utility to carry out chemical transformations with the 
induction of chirality. In fact, some Oic derivatives have already 
been used as chiral ligands or catalysts (Figure 6).[16] 
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Figure 6. Some organocatalysts and chiral ligands derived from Oic. 
It should be noted that all the applications mentioned above 
(Figures 2–6) concern compounds containing the same Oic 
stereoisomer, namely that exhibiting a (2S,3aS,7aS) 
stereochemistry [hereafter denoted[17] as (S,S,S)Oic or (S,S,S)-1, 
Figure 7]. Actually, this is the only Oic stereoisomer whose 
applications in different fields have been thoroughly explored and 
this is due to the easy accessibility to this particular template in 
enantiomerically pure form. It is, in fact, the lack of effective 
synthetic methodologies for ready accessibility to the other Oic 
stereoisomers that has limited their applications to date. The same 
holds true for all ( Me)Oic stereoisomers. 
In recent years, the relevant properties exhibited by compounds 
containing (S,S,S)Oic has stimulated the search for synthetic 
methodologies leading to other Oic stereoisomers, particularly 
those characterized by a cis-configuration at the ring junction, as 
well as to their -methylated counterparts. The present paper 
intends to illustrate the progress of the synthetic methods 
developed for the construction of all cis-fused Oic and ( Me)Oic 
stereoisomers (Figure 7)[17] in enantiomerically pure form either by 
asymmetric synthesis or by combining a racemic synthesis with a 
resolution procedure. 
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Figure 7. Structure of Oic and ( Me)Oic stereoisomers with a cis-fused bicyclic skeleton.
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Various synthetic strategies have been devised for the 
preparation of the cis-fused stereoisomers of Oic. The most 
effective procedures involve the hydrogenation of a double bond 
connecting the bridgehead carbons of appropriate precursors such 
as the indole,[18] indoline[19,20] or bicyclic enamine[21] derivatives 
depicted in Figure 8 (type A substrates). The hydrogenation 
process ensures the cis relative disposition of the hydrogen atoms 
at the ring junction, and the construction of the cis-fused 
octahydroindole-2-carboxylic acid system is therefore 
accomplished in a straightforward manner. 
Alternatively, a number of strategies make use of starting 
materials that already exhibit a cis relative disposition of the 
protons bonded to the carbon atoms involved in the fusion (type B 
substrates, Figure 8), but require further modifications such as ring 
closure[22] or contraction[23] or the incorporation of the carboxylic 
acid moiety at the  carbon.[23,24] 
In addition to the aforementioned routes, the construction of the 
cis fusion has been achieved through an intramolecular 5-exo-trig 
radical cyclization procedure (substrate C, Figure 8).[25] 
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Figure 8. Different types of precursors used for the synthesis of the cis-
fused stereoisomers of Oic and ( Me)Oic. 
2. Asymmetric procedures 
Nearly all the precursors previously disclosed have been used for 
the preparation of enantiopure cis-fused Oic stereoisomers. Most 
often, the synthetic strategies involve stereoselective 
transformations on chiral precursors but also the use of a prochiral 
synthon in combination with a chiral auxiliary has been reported. 
2.1. Auxiliary-controlled methods 
Dubuffet et al have demonstrated[24] the utility of (S)-
phenylglycinol as a chiral auxiliary for the preparation of the cis-
fused bicyclic pyrrolidinone 8, which was further elaborated to 
generate enantiomerically pure (S,S,S)-1 (Scheme 1). Thus, the 
condensation of the keto-acid 3 and (S)-phenylglycinol (4) in 
toluene with azeotropic removal of water gave the tricyclic lactam 
5. The auxiliary induced the simultaneous establishment of the two 
contiguous stereogenic centers with a complete stereochemical 
control, and provided lactam 5 as a single stereoisomer. The 
stereoselective replacement of the oxazolidine C–O bond with a 
hydrogen atom was achieved by treatment of 5 with triethylsilane 
in the presence of boron trifluoride etherate. The Lewis acid 
presumably coordinates with the oxazolidine oxygen to promote 
the formation of an iminium ion and the departing oxygen directs 
the delivery of hydride with retention of configuration. The 
cleavage of the chiral auxiliary was then achieved by treatment of 6 
with thionyl chloride, followed by hydrolysis of the resulting 
enamide (7) under acidic conditions. Subsequent standard synthetic 
transformations on the lactam moiety of pyrrolidinone 8 gave rise 
to 10 that was further hydrogenated to afford (S,S,S)-1 in 99% 
enantiomeric excess. Unfortunately, details were not provided in 
this patent concerning the stereoselectivity of the hydrogenation 
reaction. Presumably, the steric hindrance produced by the 
cyclohexane moiety in 10 plays a crucial role in stereodirecting the 
hydrogenation reaction to give (S,S,S)-1 rather than the isomer 
exhibiting an (R,S,S) stereochemistry. Moreover, no conclusion can 
be drawn regarding the effectiveness of the synthetic method due 
to the lack of information on the yield of each individual step. 
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Scheme 1. Synthesis of enantiomerically pure (S,S,S)Oic by condensation 
of (2-oxocyclohexyl)acetic acid and (S)-phenylglycinol, according to ref. 
24. Reagents and conditions: a) Toluene, reflux, Dean-Stark; b) Et3SiH, 
BF3·OEt2, CH2Cl2, reflux; c) SOCl2, CH2Cl2, reflux; d) aq. H2SO4 5M; e) 
Tf2O, iPr2EtN, CH2Cl2, r.t.; f) LiCN, 12-crown-4 ether, THF, r.t.; g) aq. 
HCl 20%, reflux; h) H2  (5 bar), 10% Pd/C, AcOH, r.t.; then TsOH, 30 ºC. 
Data on the reaction yields are not provided by the authors. 
2.2. Substrate-controlled methods 
Alternatively, Dubuffet et al reported[21b] the preparation of 
enantiomerically pure (S,S,S)-1 by employing enantiopure N-Boc-
-iodo-L-alanine benzyl ester (13) as the source of chirality 
(Scheme 2). This compound, which is easily derived from L-serine 
in a four-stage sequence,[26] was reacted with the enamine (12) 
derived from cyclohexanone and pyrrolidine to give 14. Removal 
of the N-Boc protecting group provided an amino ester which 
cyclized to 15 upon heating under acidic conditions. Subsequent 
catalytic hydrogenation ensured the cis relative disposition of the 
hydrogen atoms at the ring junction and cleaved the benzyl ester, 
thus yielding (S,S,S)-1 in 87% yield and 99% enantiomeric excess. 
Also in this case, details were not given by the authors concerning 
the stereoselectivity of the hydrogenation step that could 
presumably render a small percentage of epimeric (S,R,R)-1 
together with the main product. Probably, the process proceeds in a 
quite diastereoselective fashion towards (S,S,S)-1 due to the 
stereodirecting effect produced by the carboxylic acid moiety in 15. 
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Scheme 2. Synthesis of enantiomerically pure (S,S,S)Oic from an L-alanine 
derivative, according to ref. 21b. Reagents and conditions: a) PhSO3H, 
BnOH, CCl4, reflux; b) Boc2O, aq. NaOH, THF, r.t.; c) TsCl, Py, –10 ºC; d) 
NaI, acetone, r.t.; e) CH3CN, reflux; f) TFA, CH2Cl2, r.t.; g) TsOH, toluene, 
reflux, Dean-Stark; h) H2 (5 bar), 10% Pt/C, AcOH, r.t. 
The preparation of (S,S,S)-1 has also been achieved through the 
cyclization of a radical carbon generated on the side chain of an L-
aspartic acid derivative (Scheme 3).[25] The photochemical 
treatment of the N-hydroxy-2-thiopyridone ester 17 produced a 
radical that underwent cyclization in moderate yield to provide a 
separable mixture of the (S,R,R) and (S,S,S) diastereoisomers, from 
which a derivative of (S,S,S)Oic could be isolated after several 
transformations. However, no details were provided by the authors 
concerning the diastereoisomeric ratio attained upon the cyclization, 
the procedure for the isolation of 18a or the effectiveness of the 
subsequent transformations carried out on this compound. All these 
factors render the synthetic procedure not very convenient for the 
preparation of (S,S,S)-1. Moreover, the protecting groups in 19 
seem not to be very appropriate for undertaking further 
transformations, since they need to be eliminated under basic or 
acidic conditions that could affect the amino acid enantiomeric 
purity. 
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Scheme 3. Synthesis of an (S,S,S)Oic derivative in enantiomerically pure 
form starting from an L-aspartic acid derivative, according to ref. 25. 
Reagents and conditions: a) 3-Bromocyclohex-1-ene, K2CO3, CH3CN, r.t.; 
b) p-BrC6H4COCl, K2CO3, acetone, r.t.; c) 2N NaOH, DMF, r.t.; d) 
iBuOCOCl, N-methylmorpholine, N-hydroxy-2-thiopyridone, Et3N, THF, –
15 ºC; e) THF, h , r.t.; f) Ni Raney, EtOH, r.t.; g) TFA, r.t.; h) EtBr, 
NaHCO3, DMF. The procedure for the isolation of 18a and the yields of the 
subsequent steps are not provided by the authors. 
The formation of the octahydroindole system has also been 
attained by ring-closing metathesis of a suitable diallylated proline 
derivative (Scheme 4).[22] The starting L-glutamic acid derivative 
20 was converted into 21 following a four-step synthetic pathway 
that emcopased an almost complete diastereoselective allylation of 
the Li-enolate of 20, deprotection of the amino function, thermal 
cyclization and reprotection of the lactam. Next, a selective 
reduction of the lactam 21 to the hemiaminal 22, followed by an 
acid-catalyzed allylation reaction provided a 25:75 syn/anti mixture 
of the diallylated products 23. Subsequent ring-closing metathesis 
of the isolated syn stereoisomer and hydrogenation of the resulting 
bicyclic compound provided the N-Boc protected methyl ester 
derivative of (S,S,S)Oic. 
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Scheme 4. Synthesis of an (S,S,S)Oic derivative in enantiomerically pure 
form by ring-closing metathesis, according to ref. 22a. Reagents and 
conditions: a) HMDS, nBuLi, allyl bromide, THF, –78 ºC; b) 1.TFA, 
CH2Cl2, 0 ºC; 2. Toluene, reflux; c) Boc2O, DMAP, THF, r.t.; d) LiEt3BH, 
THF, –78 ºC; e) Allyltributylstannane, TBDMSOTf, CH2Cl2, –78 ºC; pure 
23a was isolated by column chromatography; f) Grubbs catalyst, CH2Cl2, 
r.t.; g) H2 (2 bar), 5% Pd/C, EtOH, r.t. 
The introduction of the allyl group at the C5 position of 
hemiaminal 22 (Scheme 4) in such a low selectivity towards the 
syn stereoisomer renders this strategy not practical for the 
multigram preparation of (S,S,S)-1. However, Hanessian et al have 
recently described[22b] an improved syn-allylation reaction via 
related N-acyl iminium ion chemistry (Scheme 5). After an 
extensive optimization of the solvent, Lewis acid and protecting 
groups used, allylation of aminal 26 occurred with an 85:15 
syn/anti selectivity, when performed in toluene with 
allyltributylstannane in the presence of boron trifluoride etherate. 
The major isomer (27a), which was easily separated by 
chromatography, underwent olefin methathesis to provide the 
corresponding carbocyclization product in excellent yield.[22b] 
Therefore, the overall synthetic strategy depicted in Scheme 4 
could be efficiently applied to the preparation of (S,S,S)-1 if aminal 
26 (Scheme 5) would be employed as the substrate for the key syn-
allylation step. 
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Scheme 5. Improved synthesis of a syn-diallylated compound that can serve 
as a precursor for (S,S,S)Oic. Reagents and conditions: a) 
Allyltributylstannane, BF3·OEt2, toluene, –78 ºC. 
Among all the strategies reported for the preparation of 
enantiopure (S,S,S)-1 where the overall stereochemistry is directly 
influenced by an existing chiral center in the starting material, the 
most simple one involves the hydrogenation of (S)-indoline-2-
carboxylic acid, (S)-28. This is because the hydrogenation of this 
bicyclic precursor ensures the required cis relative disposition of 
the bridgehead atoms of the octahydroindole system in a single 
step. 
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Scheme 6. Synthesis of enantiomerically pure (S,S,S)Oic by hydrogenation 
of (S)-indoline-2-carboxylic acid or its ethyl ester derivative, according to 
ref. 19,20. Reagents and conditions: i) H2 (30 bar), 5% Rh, MeOH, 60 ºC; 
recrystallization from dioxane/H2O; ii) H2 (50 bar), 10% Pd/C, AcOH, 50 
ºC; recrystallization from Et2O; iii) H2 (12 bar), 5% Rh/Al2O3, NaOH, H2O, 
50 ºC; recrystallization from MeOH; iv) H2, PtO2, AcOH, 60 ºC, 
recrystallization from EtOH; v) H2 (50 bar), 7.5% Pd/C, EtOH, 60 ºC; then 
aq. NaOH 30%, 30 ºC; recrystallization from THF/H2O.  
Several catalytic systems and reaction conditions have been 
reported to date for this transformation (Scheme 6).[19] Vincent et 
al were the first to describe that the hydrogenation of (S)-28 
provides (S,S,S)-1 in good yields when performed under pressure 
using rhodium[19a] or palladium/carbon[19b,c] as a catalyst (Scheme 6, 
hydrogenation conditions i and ii). Presumably, the hydrogenation 
is highly selective in both cases, albeit the diastereoisomeric ratio 
has been stated by the authors only for the palladium-catalyzed 
reaction, which afforded a 90:10 mixture of (S,S,S)-1 and (S,R,R)-
1.[19c] On this basis, the low isolated yield of (S,S,S)-1 (66%) might 
be attributed to an inefficient purification, carried out by 
recrystallization from diethyl ether. After that, a rhodium-catalyzed 
hydrogenation of (S)-28 at lower pressure of hydrogen (12 instead 
of 30 or 50 bar) and under basic reaction conditions was disclosed 
in a patent (Scheme 6, hydrogenation conditions iii), although the 
stereoselectivity was not mentioned.[19d] More recently, we have 
shown that the use of platinum oxide as a catalyst allows the 
hydrogenation of (S)-28 to proceed at atmospheric pressure 
(Scheme 6, hydrogenation conditions iv) and this means a very 
practical advantage for a multigram scale production.[19e] Under 
these catalytic conditions, the carboxyl group in (S)-28 was quite 
effective in orienting the approach of hydrogen and also afforded a 
90:10 mixture of epimers, from which (S,S,S)-1 was isolated in 
85% yield by recrystallization from ethanol. Additionally, the 
palladium-catalyzed hydrogenation of the ethyl ester derivative (S)-
29 has been described in a patent (Scheme 6, hydrogenation 
conditions v).[20b] Although the stereoselectivity of the process is 
not mentioned, the catalytic reduction of (S)-29 under pressure of 
hydrogen, followed by aqueous hydrolysis and recrystallization, is 
claimed to afford (S,S,S)-1 in 40% overall yield. 
The stereoselectivity reported[19c,e] for the hydrogenation of (S)-
28 under different conditions (Scheme 6) suggests that the 
hydrogenation of compounds 10 and 15 depicted in Schemes 1 and 
2, respectively, might occur in a highly selective fashion although 
data on the selectivity observed were not provided.[21b,24] 
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All the synthetic routes described so far addressed the 
preparation of the (S,S,S)Oic stereoisomer. Obviously, they could 
be applied to the synthesis of enantiomeric (R,R,R)Oic provided 
that starting materials with the opposite absolute configuration are 
employed. 
In contrast, just a single methodology has been described for the 
preparation of (R,S,S)Oic in enantiomerically pure form. It involves 
an epimerization reaction at the  position of enantiopure (S,S,S)-
1.[19c,e] Probably, this is the most simple approach to access 
(R,S,S)Oic because any other retrosynthetic disconnection would 
require the use of more complex starting materials. Specifically, 
Vincent et al[19c] reported the epimerization of enantiopure (S,S,S)-
1 by treatment with salicylaldehyde for 1.5 hours under acidic 
conditions to afford a 50:50 mixture of (S,S,S)-1 and (R,S,S)-1 
(Scheme 7). The desired (R,S,S) stereoisomer was isolated from the 
mixture after consecutive preferential crystallizations, thus making 
the synthesis very laborious and the global yield quite low (30%).  
N
H
CO2H
H
H
N
H
CO2H
H
H
(R,S,S)-1
(R,S,S)Oic
(S,S,S)-1
+
50:50
N
H
CO2H
H
H
(S,S,S)-1
a
(30% isolated yield, >99%ee)  
Scheme 7. Synthesis of enantiomerically pure (R,S,S)Oic according to ref. 
19c. Reagents and conditions: a) Salicylaldehyde, AcOH, reflux, 1.5 h; 
crystallization from EtOH to eliminate (S,S,S)-1; recrystallizations of 
(R,S,S)-1 from EtOAc and EtOH/EtOAc. 
On this basis, we have reported an optimized method for the 
preparation of (R,S,S)-1 (Scheme 8),[19e] which combined an 
improved epimerization of (S,S,S)-1 with a more competitive 
procedure for the separation of epimers, other than preferential 
crystallizations. Enantiomerically pure (S,S,S)-1 was submitted to 
the aforementioned acidic epimerization conditions under a 
prolonged reaction time (24 hours), and this led to a considerable 
enrichment of the desired epimer in the diastereoisomeric mixture, 
with the final (S,S,S)-1/(R,S,S)-1 ratio being 23:77. Next, the 
mixture was submitted to condensation with trichloroacetaldehyde, 
which served as a tool for discrimination between the epimers. 
Thus, (R,S,S)-1 provided the tricyclic oxazolidinone (S,S,S,R)-30 
whereas (S,S,S)-1 remained unreacted (Scheme 8). 
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Scheme 8. Synthesis of enantiomerically pure (R,S,S)Oic according to ref. 
19e. Reagents and conditions: a) Salicylaldehyde, AcOH, reflux, 24 h; b) 
CCl3CHO, CH3CN, r.t.; c) 3N HCl/EtOAc, r.t. 
This novel separation procedure was inspired in reported 
investigations dealing with the highly stereoselective synthesis of 
bicyclic oxazolidinones derived from L-proline.[27] The 
condensation of L-proline with bulky aldehydes leads to a single 
diastereomer with the bulky group in a cis disposition relative to 
the hydrogen at the  carbon. The ease of such stereoselective 
condensation, when applied to octahydroindole-2-carboxylic acids, 
proved to be conditioned to the structural constraint of the resulting 
tricyclic system. Presumably, the formation of the oxazolidinone 
from (S,S,S)-1 was precluded due to overlapping of hydrogen 
atoms that would occur at the concave face defined by the tricyclic 
scaffold.[19e] 
The single oxazolidinone produced, (S,S,S,R)-30, was easily 
separated from unreacted (S,S,S)-1 by filtration through a short pad 
of silica and its stereochemistry was corroborated by X-ray 
diffraction analysis.[19e] Subsequent hydrolysis under acidic 
conditions allowed the isolation of the desired (R,S,S)Oic (Scheme 
8). Altogether, this combined epimerization-condensation-
hydrolysis sequence[19e] provided a 56% overall yield of (R,S,S)-1. 
This is a much higher efficiency than that corresponding to the 
combined epimerization-crystallizations method[19c] in Scheme 7 
(30%). 
The ready accessibility to oxazolidinone (S,S,S,R)-30 made it 
feasible to explore the synthesis of -substituted Oic derivatives, 
capitalizing on Germanas’ work performed on the 
trichloromethyloxazolidinone derived from L-proline,[27] and based 
on pioneering studies by Seebach.[28] These studies describe that 
the bridgehead nitrogen of the oxazolidinone derived from L-
proline is strongly pyramidalized even when an enolate is 
generated and its inversion does not take place because of the high 
steric constraints that would be associated to this change. For this 
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reason, the enolate attacks electrophiles only from the face 
previously occupied by the  hydrogen, thus leading to the 
formation of a single stereoisomer with complete retention of 
configuration at the  carbon. This behavior was named by 
Seebach as self-reproduction of chirality.[28] 
On this basis, we carried out the preparation of enantiopure 
(R,S,S)( Me)Oic[17] starting from (S,S,S,R)-30 (Scheme 9).[19e] The 
treatment of this oxazolidinone with lithium diisopropylamide 
generated an enolate that underwent alkylation with methyl iodide 
exclusively at the Si face. Single crystal X-ray diffraction analysis 
provided evidence for the alkylation reaction taking place with 
retention of configuration, that is, the trichloromethyl group and 
the newly introduced substituent are cis to each other on the exo 
side of the bicycle formed by the two five-membered rings. The 
resulting -methylated oxazolidinone (S,S,S,R)-31 was deprotected 
under acidic conditions to give the free -methylated amino acid 
(R,S,S)( Me)Oic in excellent global yield.[19e] 
N
H
H O
O
Me
CCl3
(S,S,S,R)-31
N
H
H
H
(R,S,S)-2 · HCl
(R,S,S)( Me)Oic · HCl
HCl
b 92%
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O
H
(S,S,S,R)-30
CCl3
95%
a
Me
CO2H
 
Scheme 9. Synthesis of enantiomerically pure (R,S,S)( Me)Oic according 
to ref. 19e. Reagents and conditions: a) LDA, MeI, THF, –78 ºC to –50 ºC; 
b) 6N HCl/AcOH, reflux. 
The preparation of (S,S,S)( Me)Oic required a different 
synthetic procedure because, as already mentioned, (S,S,S)-1 failed 
to undergo condensation with trichloroacetaldehyde to produce the 
corresponding oxazolidinone, (R,S,S,S)-30 (Scheme 10).[19e] The 
alternative methodology for the preparation of 
(S,S,S)( Me)Oic[15,29,30] took advantadge of the steric hindrance 
introduced by the cyclohexane group in (S,S,S)-1, which prevented 
the formation of the oxazolidinone, to induce facial selectivity on 
-alkylations taking place on an exocyclic enolate. Such an enolate 
was generated from the N-Boc protected amino ester (S,S,S)-25 
upon treatment with lithium diisopropylamide and reacted with 
methyl iodide to provide a diastereoisomeric mixture of the -
methylated compounds in 89:11 ratio (Scheme 10).[29,30] The major 
isomer was isolated pure in 75% yield after column 
chromatography. Subsequent saponification provided 
(S,S,S)( Me)Oic in the N-Boc protected form.
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N
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H
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H
H
Me
CO2Me+
d 92%
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H
H O
O
H
(R,S,S,S)-30
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Scheme 10. Synthesis of an (S,S,S)( Me)Oic derivative in enantiomerically 
pure form, according to ref. 29,30. Reagents and conditions: a) SOCl2, 
MeOH, r.t.; b) Boc2O, iPr2EtN, DMAP, THF, r.t.; c) LDA, MeI, THF, –78 
to –50 ºC; d) 1N KOH, MeOH, reflux. 
Interestingly, the -methylation reaction provided an identical 
result when performed on epimeric (R,S,S)-25 (Scheme 11) 
prepared from enantiopure (R,S,S)-1.[19e] This observation indicates 
that both epimers give rise to the same intermediate enolate and 
that the stereocontrol during the C–C bond forming reaction is 
purely driven by the steric hindrance imposed by the cis-fused 
cyclohexane group. Such an efficient facial stereodifferentiation 
translated into a preferential formation of (S,S,S)-32. The minor 
stereoisomer, (R,S,S)-32, matched a derivative which was 
separately prepared from enantiomerically pure (R,S,S)-2 (Scheme 
9), thus confirming the (S,S,S) stereochemistry of the major -
methylation product in Schemes 10 and 11. 
It is worth mentioning that the complementary methodologies 
described for the preparation of (R,S,S)( Me)Oic and 
(S,S,S)( Me)Oic in Schemes 9 and 10, respectively, have proven 
effective for the incorporation of other electrophiles at the  carbon, 
regardless of their steric and electronic characteristics.[19e,30] 
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Scheme 11. -Methylation of enantiomerically pure (S,S,S)Oic and 
(R,S,S)Oic derivatives described in ref. 30. Reagents and conditions: a) 
LDA, MeI, THF, –78 to –50 ºC. 
An analysis of the asymmetric synthetic procedures described 
above provides evidence that all the cis-fused stereoisomers of Oic 
and ( Me)Oic depicted in Figure 7 can be derived in a quite 
efficient manner from the same starting product, namely (S)-
indoline-2-carboxylic acid [(S)-28] or its enantiomer [(R)-28]. In 
particular, (S)-28 proved the most advantageous precursor for the 
preparation of (S,S,S)Oic, as shown in Scheme 6. In turn, this Oic 
stereoisomer has been employed as a substrate for the synthesis of 
(S,S,S)( Me)Oic through a stereoreselective -methylation 
reaction (Scheme 10). (S,S,S)Oic has also been transformed into 
(R,S,S)Oic by means of an epimerization process (Scheme 8), and 
then into (R,S,S)( Me)Oic (Scheme 9). Obviously, the use of (R)-
28 as the starting material would provide access to the 
enantiomeric products. The usefulness of (S)- and (R)-28 in the 
production of all the possible stereoisomers of Oic and ( Me)Oic 
characterized by a cis ring junction in optically pure form is 
illustrated in Scheme 12. 
52% yield from (S)-28
45% yield from (S)-2847% yield from (S)-28
85% yield from (S)-28
(S,S,S)Oic (S,S,S)( Me)Oic
(R,S,S)( Me)Oic
(S)-28
(R,S,S)Oic
(R,R,R)Oic (R,R,R)( Me)Oic
(S,R,R)( Me)Oic
(R)-28
(S,R,R)Oic
 
Scheme 12. Schematic representation of the accessibility to all cis-fused 
Oic and ( Me)Oic stereoisomers in enantiomerically pure form starting 
from (S)- or (R)-indoline-2-carboxylic acid. Overall yields calculated from 
(S)-28 are provided for the synthesis of the target amino acids in the free 
form or as N-protected derivatives. 
Both (R)- and (S)-28 are accessible starting materials because 
their synthesis has been actively investigated.[31] The interest on 
these compounds stems from the fact that the indoline scaffold is 
found in a wide range of alkaloid natural products,[32] biologically 
active compounds,[33] and as a part of chiral auxiliaries for 
asymmetric synthesis.[34] In particular, the preparation of (R)- or 
(S)-indoline-2-carboxylic acid has been achieved by chemical 
resolution with diverse crystallizing agents,[19a,c,20a,35] chemical 
synthesis through catalytic asymmetric hydrogenation of 
indoles,[36] intramolecular aryl aminations,[37] asymmetric 
deprotonation of N-Boc indoline followed by carbonylation,[38] and 
via enzymatic methods.[39] Moreover, both (R)- and (S)-28 have 
become commercially available. 
3. Resolution procedures 
Resolution procedures may result in a convenient alternative to 
asymmetric synthesis, in particular, when the isolation of the two 
enantiomers of a certain stereoisomer is pursued. Among the 
different procedures that allow the separation of enantiomers, 
chemical resolutions often provide moderate yields of optically 
pure material after extensive crystallizations and require working 
on a relatively large scale. This is the reason why enzymatic and 
chromatographic resolutions are becoming usual techniques for the 
production of enantiomerically pure compounds. 
3.1. Chemical resolutions 
Crystallizations of diastereoisomeric salts of different 
(S*,S*,S*)Oic derivatives have been reported.[18,21c,40] In particular, 
Blankley et al achieved[18b,c] the resolution of the racemic N-
benzoyl derivative (S*,S*,S*)-36 by separation of the 
diastereomeric salts of (S)- -phenylethylamine by means of 
crystallizations (Scheme 13). The L-tartrate salts of the tert-butyl 
ester derivative (S*,S*,S*)-37 also proved useful for the same 
purpose. The process was laborious in both cases and suffered from 
low isolated yields given that several crystallizations were 
necessary. The acidic hydrolysis of the (S)- -phenylethylamine salt 
isolated from (S*,S*,S*)-36 provided the all-cis fused Oic 
stereoisomer exhibiting levorotatory optical activity. Conversely, 
the hydrolysis of the L-tartatre salt derived from (S*,S*,S*)-37 
rendered the levorotatory tert-butyl ester derivative. Even if no 
further details were given by the authors[18b,c] concerning the 
assignment of absolute configurations, the isolated compounds can 
be identified as (S,S,S)-1 and (S,S,S)-37, respectively, by 
comparison of their optical rotations to values reported in the 
literature.[20a,25]  
The preparation of the racemic precursors (S*,S*,S*)-36 and 
(S*,S*,S*)-37 was achieved by hydrogenation of the indole ester 34 
under acidic conditions, using rhodium/carbon as the catalyst 
(Scheme 13).[18b,c] The use of this starting material showed the 
advantage of providing a unique Oic stereoisomer, namely, that 
exhibiting a cis relative disposition of the two bridgehead hydrogen 
atoms and that at the  position, whereas, as mentioned above, the 
hydrogenation of indoline-2-carboxylic acid (28) affords a 10% of 
the epimer at the  carbon (Scheme 6). In spite of this advantage, 
only a 32% overall isolated yield of racemic (S*,S*,S*)-1 from 34 
was reported.[18b,c] Such a poor yield was mainly due to an 
inefficient recrystallization of the hydrochloride salt of (S*,S*,S*)-
35 prior to the ester hydrolysis. 
In addition, the chemical resolution of the benzyl ester derivative 
of (S*,S*,S*)-1 using either dibenzoyl-L-tartaric acid or N-Cbz 
protected L-phenylalanine as the resolving agents has been outlined 
in patents.[21c,40] However, insufficient information about the 
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assignment of the absolute configuration of the isolated 
enantiomers or the stereochemical integrity of the racemic 
precursors is provided. 
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Scheme 13. Synthesis of (S,S,S)Oic derivatives in enantiomerically pure 
form by chemical resolution, according to ref. 18b. Reagents and conditions: 
a) H2 (Parr apparatus), conc. H2SO4, 10% Rh/C, EtOH; b) aq. HCl 15%, 
reflux; recrystallization from CH3CN/EtOAc; c) aq. NaOH; 
recrystallization from CH3CN; d) 2N NaOH, BzCl, H2O, 5 ºC; 
recrystallization from EtOH/H2O; e) (S)- -phenylethylamine, MeOH; then 
EtOAc; recrystallization from MeOH/EtOAc; f) HCl, MeOH/H2O, r.t.; g) 
conc. HCl, H2O, reflux; filtration through Amberlite IR-120; two 
recrystallizations from MeOH/EtOH; h) isobutylene, conc. H2SO4, dioxane, 
r.t., sealed tube; i) L-tartaric acid, THF; recrystallization from 
EtOAc/MeOH, 0 ºC; j) aq. Na2CO3 5%, Et2O. 
3.2. Enzymatic resolutions 
Enzymatic processes for producing optically active Oic 
derivatives have been addressed only recently and just two 
successful examples have been described to date. Hirata et al 
disclosed in a patent[41] an efficient resolution of the ethyl ester 
(S*,S*,S*)-38 by hydrolysis with an esterase, derived from a 
Chromobacterium SC-YM-1 strain, working in an aqueous 
solution buffered at pH 8 (Scheme 14). The process allowed the 
isolation of enantiopure (S,S,S)-39 in 49% yield. Conversely, the 
optical purity of the unreacted ester, (R,R,R)-38, was slightly lower 
(96% ee). Under similar conditions, the same enzyme was also able 
to asymmetrically hydrolyze the ester group of the N-Boc protected 
derivative (S*,S*,S*)-40, thus allowing the production of 
enantiopure (S,S,S)-41 in 45% yield. The (R,R,R) enantiomer of the 
starting ester was recovered in 39% yield and high optical purity. 
Despite the fact that no details were provided about the assignment 
of the absolute configuration of each enantiomer, the acids formed 
are claimed to be (S,S,S). 
The racemic substrates used for the aforementioned enzymatic 
resolutions were prepared[41] by protection of the amino moiety in 
(S*,S*,S*)-35 (Scheme 13) with Cbz or Boc using standard 
procedures. In turn, the latter compound was obtained by 
hydrogenation of the indole derivative 34 under slightly different 
conditions to those reported in Scheme 13 [H2 (4 bar), conc. H2SO4, 
5% Rh/C, EtOH, 60 ºC, 10 h; 83% yield]. 
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Cbz-(S,S,S)Oic
N
CO2H
H
H
(R,R,R)-38
Cbz-(R,R,R)Oic-OEt
N
CO2Et
H
H
+
 (S*,S*,S*)-38
N
CO2Et
H
H
a
Cbz Cbz Cbz
49% yield
>99% ee
50% yield
96% ee
45% yield
>99% ee
39% yield
99% ee
 
Scheme 14. Synthesis of (S,S,S) and (R,R,R)Oic derivatives in 
enantiomerically pure form by enzymatic resolution, according to ref. 41. 
Reagents and conditions: a) Esterase 160A189Y363term derived from 
Chromobacterium SC-YM-1 strain, phosphate buffer pH 8, 30 ºC, 30h; b) 
Esterase 160A189Y363term derived from Chromobacterium SC-YM-1 
strain, phosphate buffer pH 8, 30 ºC, 40 h. 
More recently, we reported[39a] an alternative enzymatic 
resolution of a racemic (S*,S*,S*)Oic derivative (Scheme 15). The 
methodology employed a lipase for enantiomer discrimination 
during a highly selective carbamate formation. Candida antarctica 
lipase type A exhibited high enantioselectivity towards both the 
methyl and benzyl esters derived from (S*,S*,S*)-1 when using 
diallyl carbonate as the alkoxycarbonylating agent and working in 
tert-butyl methyl ether. However, the activity showed by the lipase 
was superior for the more sterically hindered benzyl ester, 
(S*,S*,S*)-42 (Scheme 15). In this case, the reaction proceeded 
highly efficiently, with an E-value >200 and a 50% conversion, 
thus providing excellent yields of the starting material (R,R,R)-42 
and the N-allyloxycarbonyl derivative (S,S,S)-43, which were 
isolated in high optical purity. The absolute configurations of both 
compounds were assigned after transformation of (R,R,R)-42 into a 
derivative of known stereochemistry.[39a] 
(S,S,S)-43
Alloc-(S,S,S)Oic-OBn
N
CO2Bn
H
H
(R,R,R)-42
(R,R,R)Oic-OBn
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H
H
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46% yield
98% ee
Alloc
 
Scheme 15. Synthesis of (S,S,S) and (R,R,R)Oic derivatives in 
enantiomerically pure form by enzymatic resolution, according to ref. 39a. 
Reagents and conditions: a) Diallyl carbonate, candida antarctica lipase 
type A, tBuOMe, 30 ºC, 250 rpm, 72 h. 
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The preparation of the starting racemic benzyl ester (S*,S*,S*)-
42 is described in the next section. 
In contrast to the excellent resolution achieved for the 
(S*,S*,S*)Oic stereoisomer, the lipase-catalysed process failed to 
resolve several racemic derivatives of (R*,S*,S*)Oic.[42] Although 
a good conversion was achieved during the carbamate formation 
also in this case, the optical purity of the resulting compounds was 
poor.[42] On the other hand, no attempt to enzymatically resolve 
any ( Me)Oic-based substrate has been described, presumably 
because the increased steric crowding at the  carbon would limit 
the access to the active site of enzymes, as happens for most -
tetrasubstituted -amino acids.[43] 
3.3 Chromatographic resolutions 
High performance liquid chromatography (HPLC) using chiral 
stationary phases is nowadays considered a very useful tool for 
producing enantiomerically pure compounds both in the academic 
and industrial fields.[44] In this context, our group has developed[45] 
efficient methodologies for the preparation of significant quantities 
of a variety of unnatural amino acids in optically pure form by 
performing HPLC resolution of racemic precursors on chiral 
columns.  
The efficiency of the resolution procedures carried out in our 
lab[45] relies on the use of columns containing polysaccharide-
derived stationary phases in which the chiral selector is covalently 
bonded to the silica gel matrix. These so-called immobilized phases 
have recently become commercially available as Chiralpak  IA,[46] 
IB,[47] and IC[48] (the first HPLC resolutions carried out in our 
group used columns of this type made in the laboratory) and 
combine the advantages of the traditional coated polysaccharide-
derived phases with the robustness associated to covalent 
linkage.[46–50] They are therefore characterized by an excellent 
chiral recognition ability together with a remarkable loading 
capacity and wide solvent compatibility. The two latter points are 
of particular relevance when separations on a preparative scale are 
envisaged, because the solubility of the sample on the eluent is 
crucial to achieve high efficiency. The Chiralpak  columns 
mentioned above are stable in the presence of all organic solvents, 
at variance with non-immobilized polysaccharide-derived phases, 
which are compatible only with hydrocarbon/alcohol mixtures. 
Needless to say, the latter combination of solvents is not 
appropriate to reach high concentrations of most organic 
compounds, which means a clear limitation for preparative 
purposes. 
Recently, we have applied this technique to gain access to all 
Oic and ( Me)Oic stereoisomers depicted in Figure 7 in optically 
pure form and multigram quantities. In all cases, the HPLC 
resolution was carried out on a racemic precursor of the target 
amino acid bearing the carboxylic acid and amino moieties 
adequately protected. Several aspects were taken into account to 
appropriately select the protecting groups. Firstly, these groups 
should be introduced through simple high-yielding transformations 
or, even better, be already present during the synthetic pathway. 
Such protecting groups should be also removable under mild 
reaction conditions that do not risk the optical purity of the 
resolved material if subsequent synthetic transformations are 
necessary. This issue is of particular relevance in the case of Oic 
derivatives, where an epimerization-prone -proton is present. 
Other considerations for appropriate selection of the protecting 
groups included the ease of monitoring the chromatographic 
process by UV detection as well as the effect of the derivatization 
on solubility. The latter point is crucial for performing preparative-
scale chromatography, in which case, the loading capacity of the 
column, and therefore the efficiency of the process, depend 
dramatically on the solubility of the sample in the mobile phase as 
well as in the solvent used for injection. On these bases, protecting 
groups of the carbamate type typically employed for peptide 
synthesis were used for the amino moiety while the carboxylic acid 
was derivatized as an ester. Accordingly, different combinations of 
the Boc or Cbz N-protecting groups and the methyl or benzyl esters 
were tested for the racemic precursors of Oic and ( Me)Oic to be 
resolved (for the Oic derivatives the methyl ester was not 
considered to avoid the risk of epimerization at the  position in 
the subsequent saponification step).  
The resolution of the different derivatives prepared from each 
Oic and ( Me)Oic stereoisomer was initially tested at the analytical 
level in 250  4.6 mm ID Chiralpak  IA, IB and IC columns using 
mixtures of n-hexane/isopropanol as the eluent. The effect 
produced by the addition of different percentages of other solvents 
(such as acetone, chloroform or tert-butyl methyl ether) to the 
mobile phase was also tested. This screening revealed the 
compounds depicted in Figure 9 to be the most convenient 
derivatives to be subjected to preparative chromatographic 
resolution. Among the (S*,S*,S*)Oic precursors tested, the best 
separation was observed for that bearing the Boc and benzyl ester 
groups when injected into the IA column, whereas IB showed the 
best chiral distinction capability for the (R*,S*,S*)Oic derivative 
containing a Cbz group. As mentioned above, only the benzyl ester 
was tested for the Oic substrates. In comparison, both the benzyl 
and methyl esters were considered for the ( Me)Oic derivatives, 
with the latter leading to superior enantioseparations, particularly, 
on the IC column.  
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Figure 9. Racemic Oic and ( Me)Oic derivatives subjected to preparative-
scale HPLC resolution on chiral columns. 
It is worth mentioning that the three columns used are 
considered somehow complementary and, indeed, complete 
baseline separation of peaks was achieved for almost all the 
compounds tested in at least one of them. In any case, since these 
assays were not intended for analytical purposes but to be extended 
to a preparative scale, maximum peak resolution was pursued. In 
some cases, addition of a cosolvent to the initial n-
hexane/isopropanol eluent mixture proved highly detrimental to the 
separation or resulted in enhanced enantiodiscrimination but at the 
cost of significant peak broadening. However, in other cases, the 
presence of tert-butyl methyl ether in the mobile phase led to the 
improvement of both factors, together with increased sample 
solubility. Table 1 lists the final optimized conditions established at 
the analytical level for the resolutions of the Oic and ( Me)Oic 
derivatives depicted in Figure 9.[51–53] The chromatographic 
profiles obtained under such conditions are shown in Figure 10. 
Resolution factors (RS) ranging from 3.1 to 9.5 were reached, thus 
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evidencing the high chiral recognition ability of the columns and 
providing an excellent groundwork for the next preparative stage. 
Table 1. Optimized conditions for the HPLC enantioseparation of Oic and 
( Me)Oic derivatives at the analytical level.[a] 
Compound[b] Column       Mobile phase (v/v) k 1  RS 
(S*,S*,S*)-44 IA nHx/iPrOH/tBuOMe 91/3/6 1.0 2.5 9.5 
(R*,S*,S*)-45 IB nHx/iPrOH 95/5[c] 1.9 1.8 3.1 
(S*,S*,S*)-46 IC nHx/iPrOH/tBuOMe 50/6/44 1.3 1.9 6.7 
(R*,S*,S*)-46 IC nHx/iPrOH/tBuOMe 65/10/25 1.5 2.1 6.0 
[a] Chiralpak® IA, IB, and IC columns (250  4.6 mm ID) were used. The 
chromatographic profiles are shown in Figure 10. Conditions: flow rate, 0.8 
mL/min (unless otherwise indicated); temperature, 25 ºC; UV detection, 
210 nm. The capacity (k ), selectivity ( ) and resolution (RS) factors are 
defined as follows: k  = (tr – t0)/t0,  = k 2/k 1, RS = 1.18 (t2 – t1)/(w2 + w1), 
where subscripts 1 and 2 refer to the first and second eluted enantiomers, tr 
(r = 1, 2) are their retention times, and w1 and w2 denote their half-height 
peak widths; t0 is the dead time.
 [b] See Figure 9. [c] Flow rate, 0.9 mL/min. 
 
 
Figure 10. Chromatographic profiles corresponding to the analytical HPLC 
resolutions presented in Table 1 for the racemic Oic and ( Me)Oic 
derivatives in Figure 9. These enantioseparation conditions were selected 
for subsequent extension to the preparative scale. 
Extension to the preparative scale was performed by scaling up 
the conditions established at the analytical level (Table 1, Figure 
10) to 250  20 mm ID Chiralpak® IA, IB or IC columns 
containing near 20-fold the amount of chiral stationary phase 
present in the analytical ones. Prior to carrying out each preparative 
separation, the loading capacity was established by working in an 
overload mode on the analytical-sized column under the conditions 
given in Table 1. This step allowed us to determine the maximum 
amount of sample that the column could hold while maintaining 
the separation of peaks. After this value was established, a 20-fold 
scaling allowed direct translation into the preparative scale. 
The preparative resolution of (S*,S*,S*)-44 is described next, as 
an example. The separation was carried out[51] by successive 
injections of the racemate on a 250  20 mm ID Chiralpak® IA 
column using a mixture of n-hexane/isopropanol/tert-butyl methyl 
ether 91/3/6 as the eluent and working at a flow rate of 16 mL/min. 
Detection was carried out by UV monitoring at 220 nm. Each 
injection consisted in 0.8 mL of a highly concentrated solution of 
the racemate in chloroform (500 mg of sample per mL of solvent) 
and was repeated every 14 minutes. The profile of one of such 
injections is shown in Figure 11.  
 
Figure 11. Preparative HPLC resolution of racemic (S*,S*,S*)-44. Profile 
corresponding to the injection of 800 L of (S*,S*,S*)-44 dissolved in 
chloroform (concentration: 500 mg solute/mL solvent). Column: 
Chiralpak® IA (250  20 mm ID). Eluent: nHx/iPrOH/tBuOMe 91/3/6. 
Flow rate: 16 mL/min. UV detection: 220 nm. The absorbance of the first 
peak is beyond the detector limit. 
Following this protocol, a total of 4.650 g of (S*,S*,S*)-44 were 
subjected to this resolution process in about 3.5 hours time. The 
product eluted was collected in three separate fractions. 
Evaporation of the first and third fractions provided 2.300 and 
2.298 g of the first and second eluted enantiomer, respectively, 
both of them in optically pure form (Figure 12), while the second 
fraction was found to contain 29 mg of a 26:74 mixture enriched 
on the second enantiomer and was discarded. Therefore, as much 
as 4.60 g of optically pure material was isolated from a total of 
4.65 g of injected racemate (that is, 99% recovering) in a single 
passage through the column. It should be noted that this efficient 
resolution process was carried out on a column size considered to 
be semi-preparative, which yet allowed the production of more 
than 1.2 g of enantiomerically pure compounds per hour.  
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Figure 12. HPLC analytical profile of the resolved enantiomers of 
(S*,S*,S*)-44. Column: Chiralpak  IA (250  4.6 mm ID). Eluent: 
nHx/iPrOH/tBuOMe 91/3/6. Flow rate: 0.8 mL/min. UV detection: 210 nm.  
Extension of the analytical conditions given in Table 1 (Figure 
10) to the preparative scale also proved very efficient for the 
remaining Oic and ( Me)Oic derivatives in Figure 9.[52,53] In each 
case, the resolution process was applied to 3.4–4.7 g of racemate. 
A minimum of 95% of the starting racemic material was isolated in 
enantiomerically pure form after a single passage through the 
column. In all cases, the sample was injected dissolved in 
chloroform at a concentration ranging from 500 to 600 mg of 
solute per mL of solvent. It should be emphasized that this 
extremely high sample concentration was essential to the high 
performance of the resolution process. As stated before, the use of 
chloroform is compatible with immobilized polysaccharide-derived 
stationary phases of the Chiralpak® type but not with the coated 
ones previously available on the market.  
Scheme 16 shows the transformation of the enantiomerically 
pure compounds isolated after the HPLC resolution step into the 
target amino acids, either in the free form or as N-protected 
derivatives. In all cases, the first eluted enantiomer is drawn at the 
upper position. The absolute stereochemistry of the 
enantiomerically pure compounds was established by comparison 
of either their specific rotations or their HPLC retention times to 
those determined for enantiopure samples obtained by asymmetric 
synthesis procedures (Schemes 6, 8–10). 
Accordingly, more than 1.50 g of each Oic and ( Me)Oic 
stereoisomer shown in Figure 7 (as such or bearing a carbamate-
type N-protecting group suitable for use in peptide synthesis) have 
been isolated in enantiomerically pure form by means of HPLC 
resolution (Scheme 16). This provides evidence that the 
chromatographic separation of enantiomers on chiral columns is 
nowadays a competitive alternative to other, more classical, 
resolution techniques. 
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Scheme 16. Isolation of all cis-fused Oic and ( Me)Oic stereoisomers in 
enantiomerically pure form after HPLC resolution. The target amino acids 
were isolated in the free form or as N-protected derivatives. The first eluted 
enantiomer is drawn at the upper position in all cases. Reagents and 
conditions: a) chiral HPLC; b) H2, Pd/C, EtOAc, r.t.; c) 1N KOH, MeOH, 
reflux. 
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Scheme 17. Synthesis of racemic (S*,S*,S*)-44, (R*,S*,S*)-45 and 
(R*,S*,S*)-46 according to ref. 51,53. Reagents and conditions: a) H2, PtO2, 
AcOH, 60 ºC [recrystallization from EtOH affords pure (S*,S*,S*)-1]; b) 
BnOH, TsOH, toluene, reflux; c) Boc2O, Me4N(OH), DMAP, THF, r.t.; d) 
salicylaldehyde, AcOH, reflux; e) CCl3CHO, CH3CN, r.t. [column 
chromatography of the mixture furnishes pure (S*,S*,S*,R*)-30]; f) 3N 
HCl/EtOAc, r.t.; g) 1. ClTMS, CH2Cl2; 2. CbzCl, iPr2EtN, r.t.; h) BnBr, 
iPr2EtN, CH2Cl2, r.t.; i) LDA, MeI, THF, –78 to –50 ºC; j) 1. MeONa, 
MeOH, r.t.; 2. CH3COCl, MeOH, reflux; k) CbzCl, iPr2EtN, CH2Cl2, r.t. 
Prior to the HPLC resolution processes, synthetic routes for the 
multigram scale preparation of the racemic precursors (S*,S*,S*)-
44,[51] (R*,S*,S*)-45,[53]  (S*,S*,S*)-46[52] and (R*,S*,S*)-46[53] 
were developed. They involved similar procedures to those 
described in Section 2.2, but employing racemic indoline-2-
carboxylic acid (rac-28) as the starting material.  
Thus, the hydrogenation of rac-28 using platinum oxide as the 
catalyst, proceeded at atmospheric pressure and led to a 90:10 
mixture of (S*,S*,S*)-1 and (R*,S*,S*)-1 (Scheme 17).[51]  The 
different solubility of these racemic compounds in comparison to 
that observed for the enantiopure counterparts (Scheme 6, iv) 
required the optimization of the recrystallization conditions, which 
finally provided pure (S*,S*,S*)-1 in 70% yield (Scheme 17). Next, 
the introduction of the orthogonal protecting groups was carried 
out by esterification of (S*,S*,S*)-1 with benzyl alcohol in the 
presence of p-toluenesulfonic acid and subsequent treatment of the 
ester obtained with di-tert-butyl dicarbonate. This provided 
(S*,S*,S*)-44 in 63% overall yield from rac-28. 
The same 90:10 mixture of (S*,S*,S*)-1/(R*,S*,S*)-1 was used 
for the synthesis of (R*,S*,S*)-45 (Scheme 17).[53]  It was subjected 
to epimerization conditions analogous to those reported for the 
enantiomerically pure version (Scheme 8). When the 23:77 mixture 
of (S*,S*,S*)-1/(R*,S*,S*)-1 thus obtained was treated with 
trichloroacetaldehyde, only the (R*,S*,S*)-1 stereoisomer led to 
the corresponding tricyclic oxazolidinone (S*,S*,S*,R*)-30, 
whereas (S*,S*,S*)-1 remained unreacted (Scheme 17). The 
oxazolidinone (S*,S*,S*,R*)-30 was easily isolated from the 
reaction mixture and submitted to hydrolysis to afford pure 
(R*,S*,S*)-1. Introduction of the Cbz group on the amino moiety 
followed by esterification with benzyl bromide afforded 
(R*,S*,S*)-45 in 35% global yield from rac-28. 
On the other hand, oxazolidinone (S*,S*,S*,R*)-30 was 
subjected to an -methylation reaction that occurred with complete 
stereoselectivity and retention of configuration (Scheme 17) as 
earlier described for the enantiomerically pure version (Scheme 9). 
The resulting -methylated oxazolidinone was treated with sodium 
methoxide in methanol to afford an N-formylated amino ester, 
which was progressed to the methyl amino ester by heating under 
reflux in the presence of acetyl chloride. Next, the introduction of 
the Cbz group on the amino moiety was carried out by treatment 
with benzyl chloroformate. Following this route, (R*,S*,S*)-46 
was prepared from rac-28 in 47% overall yield.[53] 
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Scheme 18. Synthesis of racemic (S*,S*,S*)-46 according to ref. 52. Reagents and conditions: a) H2, PtO2, AcOH, 60 ºC; b) SOCl2, MeOH, r.t.; c) Boc2O, 
iPr2EtN, DMAP, THF, r.t.; d) LDA, MeI, THF, –78 to –50 ºC; e) 3N HCl/EtOAc, r.t.; f) CbzCl, iPr2EtN, CH2Cl2, r.t.; g) 1. H2SO4, MeOH, reflux; 2. Boc2O, 
DMAP, THF, r.t.; h) H2, PtO2, AcOH, r.t. 
 
Racemic (S*,S*,S*)-46 was prepared[52] from (S*,S*,S*)-32 by 
replacement of the N-Boc protecting group by Cbz (Scheme 18). In 
turn, (S*,S*,S*)-32 can be obtained by a similar route to that 
described for the enantiomerically pure compound (Scheme 10). 
Thus, transformation of the 90:10 mixture of racemic (S*,S*,S*)-1 
and (R*,S*,S*)-1, obtained by hydrogenation of rac-28, into the 
corresponding N-Boc methyl ester derivatives followed by 
methylation at the -carbon afforded a 89:11 mixture of 
(S*,S*,S*)-32 and (R*,S*,S*)-32, from which the major compound 
can be isolated pure by column chromatography (Scheme 18). 
Alternatively, the same 89:11 mixture of -methylated 
compounds, (S*,S*,S*)-32 and (R*,S*,S*)-32, may be obtained in a 
more straightforward manner starting from inexpensive indole-2-
carboxylic acid (48) (Scheme 18).[52] The hydrogenation of its N-
Boc protected methyl ester derivative (49) using platinum oxide as 
the catalyst proceeded under very mild conditions to give an 
excellent yield of (S*,S*,S*)-25. Since the hydrogenation of the 
indole system entails the simultaneous incorporation of hydrogen 
to the three stereogenic centers of the molecule, it ensures the cis 
relative disposition of the two bridgehead hydrogen atoms and that 
at the  position. Accordingly, the hydrogenation of systems such 
as 49 means the most direct general procedure for the isolation of 
(S*,S*,S*)Oic derivatives provided that protecting groups resistant 
towards catalytic hydrogenation are present. -Methylation of pure 
(S*,S*,S*)-25 provided the same 89:11 mixture of (S*,S*,S*)-
32/(R*,S*,S*)-32 than that obtained from the 90:10 (S*,S*,S*)-
25/(R*,S*,S*)-25 mixture (Scheme 18). Thus, (S*,S*,S*)-46 was 
obtained from 48 in excellent global yield (61%).[52] 
4. Concluding remarks 
In this review, we have collected the methods available for the 
synthesis of the different stereoisomers of Oic and ( Me)Oic 
exhibiting a cis stereochemistry at the ring junction, in 
enantiomerically pure form. All the different cis-fused Oic and 
( Me)Oic stereoisomers can be accessed in high optical purity 
through the adequate choice of a substrate-controlled 
stereoselective synthesis or by means of a racemic synthesis 
combined with a resolution procedure. Among the last, 
chromatographic resolutions prove especially robust to deliver 
multigram quantities of the different stereoisomers Oic and 
( Me)Oic with high optical purity. All together, the different 
methods described facilitate the provision of a variety of Oic and 
( Me)Oic stereoisomers, in enantiomerically pure form, that 
should encourage further investigations on their applications in 
peptide-based drug design and catalysis research. 
5. Abbreviations and acronyms 
Abbreviations and acronyms used in this article are summarized in 
Table 2. 
Table 2.  
Ac 
Alloc 
aq. 
Bn 
Boc 
Bz 
Cbz 
conc. 
Cy 
DMAP 
DMF 
ee 
HMDS  
LDA 
nHx 
Oic 
Py 
rac 
r.t. 
TBDMSOTf 
THF 
TFA 
Tf 
TMS 
Ts 
acetyl 
allyloxycarbonyl 
aqueous 
benzyl 
tert-butoxycarbonyl 
benzoyl 
benzyloxycarbonyl 
concentrated 
cyclohexyl 
4-dimethylaminopyridine 
N,N-dimethylformamide 
enantiomeric excess 
hexamethyldisilazane 
lithium diisopropylamide 
n-hexane 
octahydroindol-2-carboxylic acid 
pyridine 
racemic 
room temperature 
tert-butyldimethylsilyl trifluoromethanesulfonate 
tetrahydrofuran 
trifluoroacetic acid 
trifluoromethanesulfonyl 
trimethylsilyl 
para-toluenesulfonyl 
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